A.I. Burnasyan FMBC clinical bulletin. 2026 № 4
The Use of Transarterial Chemoembolization with Drug-Saturated Microspheres
in Malignant Liver Lesions: A Literature Review
A.A. Zavialov, M.V. Popov, V.A. Melkumyan, M.Sh. Zugumova, N.G. Stepanyants, S.E. Voskanyan
A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Vadim A. Melkumyan: e-mail: melkum94@mail.ru
ABSTRACT
Transarterial chemoembolization (TACE) using drug-saturated microspheres (DEB) is a highly effective method of local therapy used for the treatment of malignant liver tumors, including hepatocellular carcinoma (HCC) and metastases of various primary tumors. The method is based on the delivery of chemotherapeutic drugs to the tumor tissue through the arterial system, followed by vascular embolization, which leads to the cessation of blood supply to the tumor and an increase in the concentration of the drug in the affected area. DEB are microspheres saturated with chemotherapeutic drugs that allow for long-term and controlled drug release, which significantly increases the effectiveness of treatment and reduces systemic toxicity.
Modern studies confirm that TACE with DEB demonstrates significant improvements in the treatment of patients with primary and metastatic malignant liver lesions, significantly increasing survival and improving the quality of life of patients. The mechanism of action of this method includes both the direct effect of a chemotherapeutic agent on tumor tissue and embolization-induced ischemia, which causes tumor necrosis. In recent years, numerous clinical trials have been conducted that confirm the effectiveness of TACE with DEB in combination with other treatment methods, such as surgery and radiotherapy, as well as in the context of treating patients with contraindications to surgery.
However, despite the positive results, the method has a number of limitations, including the risk of complications such as pain, thrombosis, and problems with drug dosage, and requires accurate visualization to achieve maximum therapeutic effect. Optimization of drug delivery methods and the development of new, more efficient microspheres remain important aspects.
This paper examines the basic principles, mechanisms of action, clinical results, as well as the prospects and challenges associated with the use of TACE with DEB in oncological practice, which makes it a key element of an integrated approach to the treatment of malignant liver diseases.
Keywords: liver cancer, liver metastases, endovascular treatment, transarterial chemoembolization, hepatocellular carcinoma, drug-saturated microspheres, TACE, DEB
For citation: Zavialov AA, Popov MV, Melkumyan VA, Zugumova MSh, Stepanyants NG, Voskanyan SE. The use of transarterial chemoembolization with drug-saturated microspheres in malignant liver lesions: literature review.. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.4:87-92. (In Russian) DOI: 10.33266/2782-6430-2026-4-87-92
REFERENCES
- Siegel R.L., Giaquinto A.N., Jemal A. Cancer Statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74;1:12-49. Doi: 10.3322/caac.21820. Epub 2024 Jan 17.
- Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global Cancer Statistics 2022: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024 May-Jun;74;3:229-263. Doi: 10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751.
- Бредер В.В., Базин И.С., Балахнин П.В., Виршке Э.Р., Косырев В.Ю., Ледин Е.В. и др. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Практические рекомендации RUSSCO, часть 1 // Злокачественные опухоли. 2023. Т.13. №3s С. 494–538 [Breder V.V., Bazin I.S., Balakhnin P.V., Virshke E.R., Kosyrev V.Yu., Ledin Ye.V., et al. Practical Guidelines for the Drug Treatment of Patients with Malignant Tumors of the Liver and Biliary Tract. RUSSCO Practical Guidelines, Part 1. Zlokachestvennyye Opukholi = Malignant Tumors. 2023;13;3s2:494–538 (In Russ.)]. Doi: 10.18027/2224-5057-2023-13-3s2-1-494-538.
- Balogh J., Victor D. III, Asham E.H., et al. Hepatocellular Carcinoma: a Review. Journal of Hepatocellular Carcinoma. 2016;3:41-53. Doi: 10.2147/JHC.S61146.
- Akinyemiju T., Abera S., Ahmed M., et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. JAMA Oncol. 2017;312:1683 – 1691. Doi: 10.1001/jamaoncol.2017.3055.
- Долгушин Б.И. Интервенционная радиология в онкологии: Национальное руководство в 3-х томах / Под ред. Б.И.Долгушина. М.: Издательский дом Видар-М, 2022. 783 с. [Dolgushin B.I. Interventsionnaya Radiologiya v Onkologii = Interventional Radiology in Oncology. National Guidelines in 3 Vol. Ed. Dolgushin B.I. Moscow, Izdatel’skiy Dom Vidar-M Publ., 2022. 783 p. (In Russ.)]. ISBN 978-5-88429-265-9.
- Machairas N., Tsilimigras D.I., Pawlik T.M. State-of-the-Art Surgery for Hepatocellular Carcinoma. Langenbecks Arch Surg. 2021 Nov;406;7:2151-2162. Doi: 10.1007/s00423-021-02298-3. Epub 2021 Aug 18. PMID: 34405284.
- Grandhi M.S., Kim A.K., Ronnekleiv-Kelly S.M., Kamel I.R., Ghasebeh M.A., Pawlik T.M. Hepatocellular Carcinoma: From Diagnosis to Treatment. Surg Oncol. 2016 Jun;25;2:74-85. Doi: 10.1016/j.suronc.2016.03.002. Epub 2016 Mar 5. PMID: 27312032.
- Liu C.Y., Chen K.F., Chen P.J. Treatment of Liver Cancer. Cold Spring Harb Perspect Med. 2015 Jul 17;5;9:a021535. Doi: 10.1101/cshperspect.a021535. PMID: 26187874; PMCID: PMC4561392.
- Crocetti L., Bargellini I., Cioni R. Loco-Regional Treatment of HCC: Current Status. Clin Radiol. 2017 Aug;72;8:626-635. Doi: 10.1016/j.crad.2017.01.013. Epub 2017 Feb 28. PMID: 28258743.
- Couri T., Pillai A. Goals and Targets for Personalized Therapy for HCC. Hepatol Int. 2019 Mar;13;2:125-137. Doi: 10.1007/s12072-018-9919-1. Epub 2019 Jan 1. PMID: 30600478.
- Shanker M.D., Liu H., Lee Y.Y., Stuart K.A., Powell E.E., Wigg A., Pryor D.I. Stereotactic Radiotherapy for Hepatocellular Carcinoma: Expanding the Multidisciplinary Armamentarium. J. Gastroenterol. Hepatol. 2021;36:873–884.
- Anwanwan D., Singh S.K., Singh S., Saikam V., Singh R. Challenges in Liver Cancer and Possible Treatment Approaches. Biochim Biophys Acta Rev Cancer. 2020 Jan;1873;1:188314. Doi: 10.1016/j.bbcan.2019.188314. Epub 2019 Nov 1. PMID: 31682895; PMCID: PMC6981221.
- Chang Y., Jeong S.W., Young Jang J., Jae Kim Y. Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. Int J Mol Sci. 2020 Oct 31;21;21:8165. Doi: 10.3390/ijms21218165. PMID: 33142892; PMCID: PMC7662786.
- Попов М.В., Аронов М.С., Восканян С.Э., Карпова О.В. Методика трансартериальной химиоэмболизации при первичных и метастатических опухолях печени // Саратовский научно-медицинский журнал. 2016. Т.12. №4. С. 716-720 [Popov M.V., Aronov M.S., Voskanyan S.E., Karpova O.V. Technique of Transarterial Chemoembolization for Primary and Metastatic Liver Tumors. Saratovskiy Nauchno-Meditsinskiy Zhurnal = Saratov Journal of Medical Scientific Research. 2016;12;4:716-720 (In Russ.)]. URL: https://cyberleninka.ru/article/n/metodika-transarterialnoy-himioembolizatsii-pri-pervichnyh-i-metastaticheskih-opuholyah-pecheni.
- Sieghart W., Hucke F., Peck-Radosavljevic M. Transarterial Chemoembolization: Modalities, Indication, and Patient Selection. J Hepatol. 2015 May;62;5:1187-95. Doi: 10.1016/j.jhep.2015.02.010. Epub 2015 Feb 12. PMID: 25681552.
- Zou J.H., Zhang L., Ren Z.G., Ye S.L. Efficacy and Safety of cTACE Versus DEB-TACE in Patients with Hepatocellular Carcinoma: a Meta-Analysis. J Dig Dis. 2016 Aug;17;8:510-517. Doi: 10.1111/1751-2980.12380. PMID: 27384075.
- Chen P., Yuan P., Chen B., Sun J., Shen H., Qian Y. Evaluation of Drug-Eluting Beads Versus Conventional Transcatheter Arterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis. Clin. Res. Hepatol. Gastroenterol. 2017;41:75–85
- Han T., Yang X., Zhang Y., Li G., Liu L., Chen T., Zheng Z. The Clinical Safety and Efficacy of Conventional Transcatheter Arterial Chemoembolization and Drug-Eluting Beads-Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Meta-Analysis. Biosci. Trends 2019;13:374–381.
- Facciorusso A., Di Maso M., Muscatiello N. Drug-Eluting Beads Versus Conventional Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma: a Meta-Analysis. Dig. Liver Dis. 2016;48:571–577.
- Wang H., Cao C., Wei X., Shen K., Shu Y., Wan X., Sun J., Ren X., Dong Y., Liu Y., et al. A Comparison between Drug-Eluting Bead-Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: a Meta-Analysis of Six Randomized Controlled Trials. J. Cancer Res. Ther. 2020;16:243–249.
- Irie T., Kuramochi M., Takahashi N. Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodule during Selective Balloon-Occluded Transarterial Chemoembolization: Measurement of Balloon-Occluded Arterial Stump Pressure. Cardiovasc. Interv. Radiol. 2013;36:706–713.
- Golfieri R., Bezzi M., Verset G., Fucilli F., Mosconi C., Cappelli A., Paccapelo A., Lucatelli P., Magand N., Rode A., et al. Balloon-Occluded Transarterial Chemoembolization: in Which Size Range Does It Perform Best? A Comparison of Its Efficacy Versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer. 2021;10:522–534.
- Hatanaka T., Arai H., Kakizaki S. Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. World J Hepatol. 2018 Jul 27;10;7:485-495. Doi: 10.4254/wjh.v10.i7.485. PMID: 30079135; PMCID: PMC6068849.
- Facciorusso A., Mariani L., Sposito C., Spreafico C., Bongini M., Morosi C., Cascella T., Marchianò A., Camerini T., Bhoori S., Brunero F., Barone M., Mazzaferro V. Drug-Eluting Beads Versus Conventional Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma. J Gastroenterol Hepatol. 2016 Mar;31;3:645-53. Doi: 10.1111/jgh.13147. PMID: 26331807.
- Lucatelli P., de Rubeis G., Rocco B., Basilico F., Cannavale A., Abbatecola A., Nardis P.G., Corona M., Brozzetti S., Catalano C., et al. Balloon Occluded TACE (B-TACE) vs DEM-TACE for HCC: a Single Center Retrospective Case Control Study. BMC Gastroenterol. 2021;21:51.
- Raoul J.-L., Sangro B., Forner A., Mazzaferro V.M., Piscaglia F., Bolondi L., Lencioni R. Evolving Strategies for the Management of Intermediate-Stage Hepatocellular Carcinoma: Available Evidence and Expert Opinion on the Use of Transarterial Chemoembolization. Cancer Treat. Rev. 2011;37:212–220.
- Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., Camerini T., Roayaie S., Schwartz M.E., Grazi G.L., et al. Predicting Survival after Liver Transplantation in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: a Retrospective, Exploratory Analysis. Lancet Oncol. 2009;10:35–43.
- Kimura H., Ohkawa K., Miyazaki M., Sakakibara M., Imanaka K., Tamura T., Sueyoshi H., Takada R., Fukutake N., Uehara H., Ashida R., Ioka T., Nakazawa T., Nakanishi K., Katayama K. Subclassification of Patients with Intermediate-Stage (Barcelona Clinic Liver Cancer Stage-B) Hepatocellular Carcinoma Using the Up-To-Seven Criteria and Serum Tumor Markers. Hepatol Int. 2017 Jan;11;1:105-114. Doi: 10.1007/s12072-016-9771-0. Epub 2016 Oct 20. PMID: 27766479.
- Bolondi L., Burroughs A., Dufour J.F., Galle P.R., Mazzaferro V., Piscaglia F., Raoul J.L., Sangro B. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. Semin Liver Dis. 2012 Nov;32;4:348-59. Doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8. PMID: 23397536.
- Лерут Я., Езари С., Фогенн М., Акенин К., Лай К. Гепатоцеллюлярный рак и трансплантация печени: от хаоса к порядку // Альманах клинической медицины. 2018. №6. С. 552-559 [Lerut Ya., Yezari S., Fogenn M., Akenin K., Lay K. Hepatocellular Carcinoma and Liver Transplantation: from Chaos to Order. Al’manakh Klinicheskoy Meditsiny = Almanac of Clinical Medicine. 2018;6:552-559 (In Russ.)]. URL: https://cyberleninka.ru/article/n/gepatotsellyulyarnyy-rak-i-transplantatsiya-pecheni-ot-haosa-k-poryadku.
- Tsurusaki M., Murakami T. Surgical and Locoregional Therapy of HCC: Tace. Liver Cancer. 2015 Sep;4;3:165-75. Doi: 10.1159/000367739. Epub 2015 Jul 10. PMID: 26675172; PMCID: PMC4608659.
- Lencioni R., de Baere T., Soulen M.C., Rilling W.S., Geschwind J.F. Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: a Systematic Review of Efficacy and Safety Data. Hepatology. 2016 Jul;64;1:106-16. Doi: 10.1002/hep.28453. Epub 2016 Mar 7. PMID: 26765068.
- Mason M.C., Massarweh N.N., Salami A., Sultenfuss M.A., Anaya D.A. Post-Embolization Syndrome as an Early Predictor of Overall Survival after Transarterial Chemoembolization for Hepatocellular Carcinoma. HPB (Oxford). 2015 Dec;17;12:1137-44. Doi: 10.1111/hpb.12487. Epub 2015 Sep 16. PMID: 26374137; PMCID: PMC4644367.
- Agrawal R., Majeed M., Aqeel S.B., Wang Y., Haque Z., Omar Y.A., Upadhyay S.B., Gast T., Attar B.M., Gandhi S. Identifying Predictors and Evaluating the Role of Steroids in the Prevention of Post-Embolization Syndrome after Transarterial Chemoembolization and Bland Embolization. Ann Gastroenterol. 2021;34;2:241-246. Doi: 10.20524/aog.2020.0566. Epub 2020 Dec 12. PMID: 33654366; PMCID: PMC7903567.
- Ogasawara S., Chiba T., Ooka Y., Kanogawa N., Motoyama T., Suzuki E., Tawada A., Nagai K., Nakagawa T., Sugawara T., Hanaoka H., Kanai F., Yokosuka O. A Randomized Placebo-Controlled Trial of Prophylactic Dexamethasone for Transcatheter Arterial Chemoembolization. Hepatology. 2018 Feb;67;2:575-585. Doi: 10.1002/hep.29403. Epub 2017 Dec 23. PMID: 28746788.
- Kudo M., Izumi N., Kokudo N., Matsui O., Sakamoto M., Nakashima O., Kojiro M., Makuuchi M. HCC Expert Panel of Japan Society of Hepatology. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 updated Version. Dig Dis. 2011;29;3:339-64. Doi: 10.1159/000327577. Epub 2011 Aug 9. PMID: 21829027.
- Cheng A.L., Amarapurkar D., Chao Y., Chen P.J., Geschwind J.F., Goh K.L., Han K.H., Kudo M., Lee H.C., Lee R.C., Lesmana L.A., Lim H.Y., Paik S.W., Poon R.T., Tan C.K., Tanwandee T., Teng G., Park J.W. Re-Evaluating Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: Consensus Recommendations and Review by an International Expert Panel. Liver Int. 2014 Feb;34;2:174-83. Doi: 10.1111/liv.12314. Epub 2013 Nov 20. PMID: 24251922.
- Zhong B.Y., Wang W.S., Zhang S., Zhu H.D., Zhang L., Shen J., Zhu X.L., Teng G.J., Ni C.F. Re-Evaluating Transarterial Chemoembolization Failure/Refractoriness: a Survey by Chinese College of Interventionalists. J Clin Transl Hepatol. 2021 Aug 28;9;4:521-527. Doi: 10.14218/JCTH.2021.00049. Epub 2021 Apr 8. PMID: 34447681; PMCID: PMC8369015.
- Kadalayil L., Benini R., Pallan L., O’Beirne J., Marelli L., Yu D., Hackshaw A., Fox R., Johnson P., Burroughs A.K., Palmer D.H., Meyer T. A Simple Prognostic Scoring System for Patients Receiving Transarterial Embolisation for Hepatocellular Cancer. Ann Oncol. 2013 Oct;24;10:2565-2570. Doi: 10.1093/annonc/mdt247. Epub 2013 Jul 14. PMID: 23857958; PMCID: PMC4023407.
- Sieghart W., Hucke F., Pinter M., Graziadei I., Vogel W., Müller C., Heinzl H., Trauner M., Peck-Radosavljevic M. The ART of Decision Making: Retreatment with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Hepatology. 2013 Jun;57;6:2261-73. Doi: 10.1002/hep.26256. Epub 2013 May 3. PMID: 23316013.
- Hucke F., Pinter M., Graziadei I., Bota S., Vogel W., Müller C., Heinzl H., Waneck F., Trauner M., Peck-Radosavljevic M., Sieghart W. How to STATE Suitability and START Transarterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. J Hepatol. 2014 Dec;61;6:1287-96. Doi: 10.1016/j.jhep.2014.07.002. Epub 2014 Jul 10. PMID: 25016222.
- Adhoute X., Penaranda G., Naude S., Raoul J.L., Perrier H., Bayle O., Monnet O., Beaurain P., Bazin C., Pol B., et al. Retreatment with TACE: The ABCR SCORE, an Aid to the Decision-Making Process. J. Hepatol. 2015;62:855–862.
- Ogasawara S., Chiba T., Ooka Y., Kanogawa N., Motoyama T., Suzuki E., Tawada A., Azemoto R., Shinozaki M., Yoshikawa M., et al. A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. PLoS One. 2015;10:e0125244.
- Op den Winkel M., Nagel D., Op den Winkel P., Trojan J., Paprottka P.M., Steib C.J., Schmidt L., Göller M., Stieber P., Göhring P., Herbst A., Rentsch M., De Toni E.N., Göke B., Gerbes A.L., Kolligs F.T. Transarterial Chemoembolization for Hepatocellular Carcinoma: Development and External Validation of the Munich-TACE Score. Eur J Gastroenterol Hepatol. 2018 Jan;30;1:44-53. Doi: 10.1097/MEG.0000000000001005. PMID: 29076939.
- Han G., Berhane S., Toyoda H., Bettinger D., Elshaarawy O., Chan A.W.H., Kirstein M., Mosconi C., Hucke F., Palmer D., Pinato D.J., Sharma R., Ottaviani D., Jang J.W., Labeur T.A., van Delden O.M., Pirisi M., Stern N., Sangro B., Meyer T., Fateen W., García-Fiñana M., Gomaa A., Waked I., Rewisha E., Aithal G.P., Travis S., Kudo M., Cucchetti A., Peck-Radosavljevic M., Takkenberg R.B., Chan S.L., Vogel A., Johnson P.J. Prediction of Survival among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: a Response-Based Approach. Hepatology. 2020 Jul;72;1:198-212. Doi: 10.1002/hep.31022. Epub 2020 May 27. PMID: 31698504; PMCID: PMC7496334.
Author contributions:
Yanina A.V. – development of the research concept and design, collection and analysis of literature, drafting of the manuscript. Godilo-Godlevsky V.A. – development of the research concept and design, data analysis, drafting and scientific editing of the manuscript. Gornov S.V. – development of the theoretical framework, development and modification of research methods, statistical data processing, scientific editing of the manuscript. Reznik E.V. – development of the research concept and design, drafting of the manuscript, approval of the final version of the article.
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Article received: 20.05.2026. Accepted for publication: 06.09.2026.